Highlights From AACR IO 2026: Breaching the Tumor Microenvironment Fortress With New CAR T and Chimeras
Three innovative studies at AACR IO 2026 presented new ways for CAR T cells and antibody-lectin chimeras to tackle...
Three innovative studies at AACR IO 2026 presented new ways for CAR T cells and antibody-lectin chimeras to tackle...
Researchers at the AACR Annual Meeting 2024 shared how AACR Project GENIE data is helping their studies.
A recap of the plenary sessions, cutting-edge science, clinical trials, and more covered by the AACR blog.
Researchers around the world are designing and implementing methods to increase access to cancer care in low-resource areas.
During his Presidential Address at the AACR Annual Meeting 2024, Philip D. Greenberg discussed research driving immunotherapy forward.
Learn about synthetic lethality and approved drugs that use this approach to treat cancer.
Dr. Alan D’Andrea spoke about a new grant looking for fresh perspectives in Fanconi anemia-related cancer research.
The closing plenary of the AACR Annual Meeting 2024 recapped basic science, prevention, clinical advances, and more.
The journey to the first approved TIL therapy began with Steven A. Rosenberg over 30 years ago.
The editors of AACR's journals highlight studies from May, including machine learning, savings from quitting smoking, and more.
Researchers at the AACR Annual Meeting 2024 examined new treatment options for brain tumors.